Ep 39: The Urine Test That Could Replace Invasive Cancer Biopsies

96% Accurate Cancer Detection — Without an Invasive Biopsy? The Breakthrough Test That Could Save Millions What if detecting cancer was as simple as giving a urine sample? No needles. No surgery. No fear. In this episode of Boombostic Health, host Bradley Bostic sits down with Curtiss McNair Jr., VP of Operations at PanGIA Biotech, to unpack one of the most groundbreaking medical innovations in decades: a urine test powered by AI that can detect multiple cancers with jaw-dropping accuracy. But this conversation isn't just about the science. It's also about the leadership and vision needed to take innovations like this from the lab to real-world patients. 🔑 Key Takeaways The Breakthrough: How PanGIA's urine test achieves 96% sensitivity, 74% precision, and an 84% F1 score in early cancer detection. Why It Matters: 2 out of 3 biopsies for prostate and brain cancer come back benign. This test could eliminate unnecessary, invasive procedures. Global Impact: Why PanGIA launched first in India, and how cultural barriers to invasive exams are driving adoption. AI in Action: How artificial intelligence identifies subtle biomarker patterns invisible to the human eye. The Leadership Gap: Why building better healthcare depends not just on new technology, but on bold leaders willing to drive systemic change. 🌍 Why You Should Listen Cancer has touched nearly every family, and early detection is the single most powerful tool we have to save lives. This episode blends cutting-edge science, practical healthcare realities, and leadership wisdom that every innovator, clinician, and patient advocate needs to hear.